PTC Therapeutics | PTCT - Current Liabilities


PTC Therapeutics reported $776.08M in Current Liabilities for its fiscal quarter ending in September of 2026.





Current Liabilities Change Date
Acadia Pharmaceuticals USD 332.22M 29.22M Sep/2026
Alnylam Pharmaceuticals USD 2.06B 550.49M Sep/2026
Amgen USD 23.23B 2.27B Sep/2026
BioCryst Pharmaceuticals USD 195.83M 13.02M Sep/2026
Biogen USD 3.9B 18.7M Sep/2026
BioMarin Pharmaceutical USD 1.6B 59.17M Sep/2026
Cytokinetics USD 353.42M 171.99M Sep/2026
Daiichi Sankyo JPY 882.78B 117.08B Sep/2026
Enanta Pharmaceuticals USD 44.73M 3.83M Dec/2025
Gilead Sciences USD 12B 982M Sep/2026
Incyte USD 1.44B 125.72M Sep/2026
Ionis Pharmaceuticals USD 435.29M 119.65M Sep/2026
Ironwood Pharmaceuticals USD 34.73M 1.88M Sep/2026
Karyopharm Therapeutics USD 117.3M 25.24M Mar/2026
Novartis USD 32.52B 777M Sep/2026
Pfizer USD 31.73B 920M Sep/2026
PTC Therapeutics USD 776.08M 5.01M Sep/2026
Puma Biotechnology USD 82.73M 3.63M Sep/2025
Roche Holding CHF 28.85B 846M Jun/2026
Sangamo BioSciences USD 47.66M 1.9M Jun/2025
Sarepta Therapeutics USD 656.35M 153.44M Sep/2026
TG Therapeutics USD 260.53M 7.97M Sep/2026
Ultragenyx Pharmaceutical USD 389M 38M Sep/2026
Vertex Pharmaceuticals USD 5B 1.06B Sep/2026
Xencor USD 76.27M 5.6M Sep/2026